Review article · 2022 · Open access

A review of patient-reported outcomes used for regulatory approval of oncology medicinal products in the European Union between 2017 and 2020

Maria Manuel Teixeira, Fábio Cardoso Borges, Paula Barão Sousa Ferreira, João Pedro Rocha, Bruno Miguel Nogueira Sepodes, Carla Torre

Frontiers in Medicine, 9, 968272 · Published 12 August 2022 · DOI 10.3389/fmed.2022.968272

Open PDFView at the publisherCite this paper

In brief

“A review of patient-reported outcomes used for regulatory approval of oncology medicinal products in the European Union between 2017 and 2020” is a 2022 review article by Maria Manuel Teixeira and 5 co-authors, published in Frontiers in Medicine. OpenAlex counts 48 citations as of 22 November 2026, which puts it in the top 8% of works published in 2022 by citations. It is open access under a CC BY licence: the full text is free to read at Frontiers in Medicine.

Citations
48
Most cited in
2025 (14)
Field-weighted impact
1.23
References
49
Authors
6

Abstract

Introduction: Cancer and corresponding available treatments are associated with substantial symptoms and functional limitations. In this context, collection of patient-reported outcomes (PRO) in clinical trials gained special interest and is recommended by regulatory authorities. Within clinical trials framework, PRO may provide evidence to support medicines approval, labeling and marketing claims. This study aims to analyze the existing evidence based on PRO as part of new oncology indications receiving positive opinions issued by the European Medicines Agency (EMA) between 2017 and 2020 and to identify PRO related label claims granted. Methodology: Oncology medicinal products and indications approved by the European Commission following a positive opinion from the EMA between 2017 and 2020 were identified. European Public Assessment Report (EPAR) and Summary of Product Characteristics (SmPC) were reviewed for each medicinal product to identify use of PRO and PRO label claims. Results: A total of 128 oncology indications, corresponding to 76 medicines, were approved; of those, 100 (78.1%) included PRO in the confirmatory clinical trials. Thirty-seven indications were supported by double-blind randomized trials and the remainder 63 by open-label trials. Out of the 104 confirmatory trials analyzed, PRO were defined as a secondary endpoint in 60 studies (57.7%), exploratory in 31 (29.8%) and as both in 13 (12.5%). In total, 54 different PRO measures (PROM) were used, of those 41 (75.9%) were disease-specific measures. Nevertheless, PROM selected relied on the EORTC (41.3%), FACIT (17.1%) and EQ-5D (29.2%) measures. A total of 76 indications (59.4%) had PRO reviewers comments included in the EPAR, however only 22 indications (17.8%) included label claims in the SmPC. The reasons identified in the EMA assessment supporting the exclusion of PRO claims were described for 34 indications (44.7%). Conclusions: Despite growing recognition of the value of PRO data for the development of improved cancer therapies, PRO implementation remains challenging. The main reasons identified in our study are related with study design, missing data, study conduct and PROM selection.

Cite this paper

Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.

APA 7

Teixeira, M. M., Borges, F. C., Ferreira, P. B. S., Rocha, J. P., Sepodes, B. M. N., & Torre, C. (2022). A review of patient-reported outcomes used for regulatory approval of oncology medicinal products in the European Union between 2017 and 2020. Frontiers in Medicine, 9, 968272. https://doi.org/10.3389/fmed.2022.968272

MLA 9

Teixeira, Maria Manuel, et al. “A review of patient-reported outcomes used for regulatory approval of oncology medicinal products in the European Union between 2017 and 2020.” Frontiers in Medicine, vol. 9, 2022, p. 968272. https://doi.org/10.3389/fmed.2022.968272.

Chicago

Teixeira, Maria Manuel, Fábio Cardoso Borges, Paula Barão Sousa Ferreira, João Pedro Rocha, Bruno Miguel Nogueira Sepodes, and Carla Torre. 2022. “A review of patient-reported outcomes used for regulatory approval of oncology medicinal products in the European Union between 2017 and 2020.” Frontiers in Medicine 9: 968272. https://doi.org/10.3389/fmed.2022.968272.

Harvard

Teixeira, M. M. et al. (2022) ‘A review of patient-reported outcomes used for regulatory approval of oncology medicinal products in the European Union between 2017 and 2020’, Frontiers in Medicine, 9, p. 968272. doi:10.3389/fmed.2022.968272.

IEEE

M. M. Teixeira, F. C. Borges, P. B. S. Ferreira, J. P. Rocha, B. M. N. Sepodes, and C. Torre, “A review of patient-reported outcomes used for regulatory approval of oncology medicinal products in the European Union between 2017 and 2020,” Frontiers in Medicine, vol. 9, p. 968272, 2022, doi: 10.3389/fmed.2022.968272.

BibTeX

@article{teixeira2022review,
  title     = {{A review of patient-reported outcomes used for regulatory approval of oncology medicinal products in the European Union between 2017 and 2020}},
  author    = {Teixeira, Maria Manuel and Borges, Fábio Cardoso and Ferreira, Paula Barão Sousa and Rocha, João Pedro and Sepodes, Bruno Miguel Nogueira and Torre, Carla},
  journal   = {Frontiers in Medicine},
  year      = {2022},
  volume    = {9},
  pages     = {968272},
  doi       = {10.3389/fmed.2022.968272},
  url       = {https://doi.org/10.3389/fmed.2022.968272}
}

Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)

Citations by year

YearCitationsShare of the best year
202222
202388
20241212
20251414
20261212

Its field-weighted citation impact is 1.23: it has been cited 1.23 times as often as the average work of the same field, type and year (1.00 is the world average).

Topic and keywords

Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Health Systems, Economic Evaluations, Quality of Life

  • patient-reported outcomes
  • regulatory approval
  • European Medicines Agency
  • European Public Assessment Reports
  • Summary of Product Characteristics
  • label claims
  • confirmatory trials
  • EORTC

Work with this paper

Most-cited papers in Economics, Econometrics and Finance

All highly cited Economics, Econometrics and Finance papers

Questions about this paper

How do I cite this paper in APA style?

Teixeira, M. M., Borges, F. C., Ferreira, P. B. S., Rocha, J. P., Sepodes, B. M. N., & Torre, C. (2022). A review of patient-reported outcomes used for regulatory approval of oncology medicinal products in the European Union between 2017 and 2020. Frontiers in Medicine, 9, 968272. https://doi.org/10.3389/fmed.2022.968272

How many times has this paper been cited?

48 times, according to OpenAlex on 22 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.

Is this paper free to read?

Yes. It is open access at Frontiers in Medicine: sign in and open the PDF from this page.

Who wrote this paper?

Maria Manuel Teixeira, Fábio Cardoso Borges, Paula Barão Sousa Ferreira, João Pedro Rocha, Bruno Miguel Nogueira Sepodes, Carla Torre.

What is the DOI of this paper?

10.3389/fmed.2022.968272, permanently at https://doi.org/10.3389/fmed.2022.968272. Sign in and open it from this page.

Bibliographic data from OpenAlex (CC0), last checked 22 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.